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Abstract
Background: In an acute care setting, more than half the inpatient population receives
antibiotics. Approximately 10% of the general population reports an allergy to penicillin. It has
been replicated in the literature with data that of those who report a penicillin allergy, up to 95%
are incorrectly identified. When a patient is admitted to the hospital with a penicillin allergy on
their electronic health record, they are at higher risk for adverse events such as a hospital
acquired infection, the occurrence of an antibiotic resistant bacteria related to receiving broader
therapy and increased healthcare utilization.
Purpose: The purpose of this project was to address the over reporting of penicillin allergies by
creating a nurse driven protocol consisting of a focused allergy history assessment to help aid
with risk stratification, future de-labeling and promotion of antimicrobial stewardship.
Methods: This was a quantitative quasi-experimental study utilizing a prospective and
retrospective chart review. There was a two-group pre/post intervention in which patients with
reported penicillin allergies were examined 3 months prior to intervention and 3 months post
implementation of the nurse led allergy de-labeling protocol admitted to four adult Norton
Healthcare inpatient hospitals (Norton Hospital Downtown, Norton Brownsboro, Norton
Audubon and Norton Women’s and Children).
Results: The number of patients from the pre-intervention group (n=8, 0.55%) to the postintervention group (n=13, 0.88%) who were de-labeled increased by 62.5%. However, a chisquare statistical test was performed and revealed that there was no statistical significance (P =
0.28) in the rate of de-labeling. De-escalation occurred in 3 patients in pre versus 1 patient in
post sample. Nursing documentation of patient interactions involving allergies resulted in 10 of

the 21 patients de-labeled in the pre- and post-intervention sample, 47.6%. The nurse driven
protocol showed 76.9% compliance and had 1131 patient interactions out of 1472 patients
admitted with penicillin allergies.
Conclusion: Although there was no statistical significance between pre- and post-group samples,
with no active intervention it was nonetheless determined to be an improvement. Additionally,
multidisciplinary education is needed for the healthcare team to enhance compliance and
promote de-labeling . In addition, developing education for the patient when allergies are delabeled and removed from the electronic health record. Nonetheless, the nurse driven tool was
successful at filling the resource gap and gathering patient data when used correctly showing the
potential it has in a multi-modal de-labeling approach within the multidisciplinary team
upholding that nurses are essential to antimicrobial stewardship programs and their role within
should be expanded.
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Background
Problem Statement
In an acute care setting, more than half the inpatient population receives antibiotics.
Approximately one fourth of patients report an allergy to an antimicrobial. Of the patients
hospitalized, 10-15% have a reported beta lactam allergy (Blumenthal et al, 2017). These
patients often times receive broader spectrum, less effective and sometimes more toxic
antibiotics. Patients who have a reported beta lactam allergy and who are treated with a
different class antibiotic have an increased risk of therapy failure and the occurrence of an
adverse event (MacFadden et al., 2016). Previous data from outpatient and inpatient settings
suggest that all patients who report a beta lactam allergy are not truly allergic to that class of
antibiotic (Blumenthal et al, 2017). In fact, 95% of those who claim an allergy and are tested
actually have no adverse effect or event and are found to actually tolerate penicillin and other
related beta lactams, demonstrating the lack of detectable penicillin-specific IgE-mediated
antibodies (Blumenthal et al, 2017). Furthermore, up to 80% of patients with a true beta lactam
allergy lose their IgE antibody sensitivity after a decade (Chua et al, 2020).
When a patient suffers an adverse reaction to penicillin in childhood, there is often times
an uncertain correlation between the underlying diagnosis and casual attribution of the penicillin
administered, leading the physician to falsely label them allergic (Edwards & Aronson, 2000). A
recent study found that primary care physicians (PCP) are the most likely to initially label a
patient allergic to penicillin (Vyles et al., 2019). Once a patient is labeled “penicillin allergic,“
patients often retain the label through adulthood (Vyles et al., 2019, Caubet et al., 2011). A
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qualitative study from 2019 found that many PCPs knew that the documented allergies were
incorrect but they were uncomfortable with using their clinical judgement to prescribe a
penicillin or change the patient’s health record in fear of a future anaphylactic reaction (Wanat
et al., 2019). Because of this oversight, the Centers for Disease Control and Prevention and the
Infectious Disease Society of America encourage thorough penicillin allergy history and
evaluation outpatient and in an inpatient acute care setting (Blumenthal et al, 2017).

Consequences of problem
Alternative antibiotics used in the clinical setting of a penicillin allergic patient may be
less efficacious and result in suboptimal outcomes (Stern et al., 2021, Trubiano et al., 2015,
Trubiano et al., 2016). A providers mindful choice to avoid penicillin may also lead to the
avoidance of other beta lactam therapy, especially cephalosporins (Macy & Blumenthal, 2018).
For example, the aminoglycoside vancomycin is less effective against methicillin-sensitive S
aureus (MRSA) bacteremia than nafcillin or the beta lactam cefazolin (Macy & Contreras, 2014).
Beta lactam antibiotics including cephalosporins like cefazolin are the mainstay of surgical
antimicrobial prophylaxis (Bratzler et al., 2013). Although the occurrence of a true cross-reactive
IgE-mediated response is very rare between a penicillin and cephalosporin, the American Society
of Health-System Pharmacist clinical guideline indicates to avoid giving patients cephalosporins
and carbapenems in the event of surgical prophylaxis if an IgE- mediated penicillin allergy is
believed to have occurred or is documented (Bratzler et al., 2013). Therefore, patients with
documented penicillin allergies often times receive less optimal alternative therapy with less
efficacy, increased cost and adverse events with antimicrobials such as clindamycin, vancomycin,
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or gentamycin, resulting in these patients being placed at an increased risk of surgical site
infections (Blumenthal et al., 2018).
The chronic overuse of broader spectrum antibiotic therapy due to inappropriate allergy
labels contributes to the growing incidence of antimicrobial resistance in the inpatient
population. This has been a catalyst for increasing number of resistant organisms such as
Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE)
and Clostridium difficile infections for patients who report a beta lactam allergy (Chua et al,
2020, Macy & Contreras, 2014). A cohort study conducted by Macy & Contrearas (2014)
compared antibiotic exposures and the prevalence rates of Clostridium difficile, MRSA, and VRE
in patients with and without a penicillin allergy at hospital admission. After two years of
observation the investigators concluded that patients labeled with a penicillin allergy were
treated with significantly more fluoroquinolones, clindamycin and vancomycin (p <0.0001) for
each antibiotic compared with the control group. Penicillin allergic patients also had 23.4% more
C difficile, 14.1% more MRSA, and 30.1% more VRE infections in comparison to the control group
(Macy & Contreras, 2014).
Beta lactam allergies have also been associated with increased hospital length of stay,
patient mortality and drug cost (Macy & Contreras, 2014, MacFadden et al., 2016). Studies have
found that the prolongation of hospitalizations in these patients seem to be arbitrated by
increased treatment failure from less effective, alternative antibiotics (Jeffres et al., 2016).
Additionally, MacFadden et al. (2016) demonstrated that patients who did not receive the
preferred beta lactam therapy as a consequence of an allergy label had greater risk for multiple
unfavorable outcomes (aOR 3.18 95% CI 1.28-7.89). These adverse events, increased lengths of
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stays, surgical site infections (SSIs) and treatment failures have shown to be amendable by
removal of the penicillin allergy label (McDaniel et al., 2017).
Treatment failures related to decreased efficacy and the unintended adverse effects of
alternative antimicrobials lead to increased cost to the patient and healthcare utilization. A study
by Li and colleagues (2014) concluded that alternative antimicrobials were more expensive than
if the patient could tolerate penicillin. Increased length of stays, SSIs, and treatment failures are
all costly outcomes that are inflated in the context of the penicillin allergic patient. Inpatients
with a listed penicillin allergy had direct drug costs ranging from no difference to $609 per
patient more than patients without a listed penicillin allergy (Macy & Contreras, 2014). A
retrospective cohort study out of California found that patients also had an average 3-year total
estimated additional healthcare expense of $64.6 million (based on an average hospital day cost
of $2,123.56 in 2012) or about 9.5 times as much as penicillin allergy testing would have cost
(Macy & Contreras, 2014). The removal of “penicillin allergy” from a patient’s medical record has
been found to be extremely cost effective thus de-labeling of unnecessary penicillin allergies
could be a monumental stride towards appropriate healthcare utilization to reduce cost while
simultaneously protecting patients from adverse outcomes.

Current Evidence Based Interventions
Greater recognition of the consequences of the penicillin allergy has led to expanded
efforts by hospitals and other healthcare organizations to develop processes by which patients
can be de-labeled as a part of their antimicrobial stewardship initiatives. There are various
methods to address inpatient beta lactam allergies. Previously, there has been routine penicillin
skin testing with various success rates. Other organizations utilized routine allergy consultation,
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with or without oral dose challenges and patient screenings performed by the pharmacist
(Blumenthal et al, 2017). Blumenthal et al. (2015) reported a pharmacy-driven patient allergy
history interview that revealed 65.6% of patients were switched to beta lactam antibiotics.
A systematic review and meta-analysis of 24 studies concluded that inpatient penicillin
allergy testing is safe and effective in ruling out a penicillin allergy (Sacco et al., 2016) . The
authors found that these patients should be evaluated and tested during their hospitalization
given its benefit for patient outcomes and antimicrobial stewardship (Sacco et al., 2016). In an
ideal world, every patient who has a penicillin allergy would be referred to an allergist for
evaluation; however, the number of allergy specialist compared to the number of patients who
report a penicillin allergy in the outpatient and inpatient setting is largely disproportional.
Similarly, the availability of trained pharmacist to conduct focused interviews of patients
admitted to the hospital documented to have a penicillin allergy proves to be the same. The ratio
is extremely unbalanced. When considering the resource limitations, this approach becomes
unrealistic and unattainable (Stern et al., 2021).
As mentioned, penicillin allergy de-labeling can take one of many forms. Evaluating the
allergy by the details of the allergy history alone utilizing a point of care assessment tool for risk
stratification could potentially de-label patients with non-immune mediated reactions which
account for 20% of all penicillin allergies (Trubiano et al., 2015). By doing this, it targets patients
with inaccurate allergy labels attached for reasons such as gastrointestinal symptoms or a family
history. This approach also targets those where previous tolerance of a penicillin can be
evaluated through a retrospective chart review. These proactive approaches require
involvement of all members of the healthcare team. Therefore, to actively manage and evaluate
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penicillin allergies, a proactive and collaborative approach is a necessity to prevent incorrect
labeling as well as strategies to both assess and de-label patients.

Purpose of Proposed Project
The purpose of this project was to assist in addressing resource limitations associated
with the evaluation of penicillin allergies by creating a nurse driven protocol consisting of a
targeted allergy history assessment tool to help segment this large population with a risk
stratification methodology to promote antimicrobial stewardship. This protocol could assist with
identifying patients who may be eligible to be directly de-labeled of their penicillin allergy or
undergo further investigation so challenge testing can be considered by an antimicrobial
stewardship team in the future. Addressing the resource limitations could potentially allow
patients to be de-labeled of this allergy more frequently leading to a reduction of potential
future adverse events, occurrence of resistant bacteria and a decrease in overall healthcare
utilization.

Objectives
1: Retrospective review of medical records prior to implementation of a nurse-driven protocol by
examining:
a. Number of appropriately de-labeled patients
b. Number of patients receiving appropriately targeted antibiotics
2: Prospective review of medical records to determine success of allergy de-labeling following
implementation of a nurse-driven protocol by examining:
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a. Compliance of complete admission screenings entered by nursing staff
b. Number of appropriately de-labeled patients
c. Number of patients receiving appropriately targeted antibiotics
3. Compare rates pre- and post-nurse-driven screening protocol of appropriate de-labeling and
appropriate targeted antibiotic therapy in patients admitted with a beta lactam allergy at Norton
Healthcare.

Theoretical Framework
This project consist of a quality improvement intervention. The PARIHS framework was used
to guide this study. PARIHS stands for ‘Promoting Action on Research Implementation in Health
Services’. The PARIHS framework proposes three components (evidence, context, and
facilitation); these factors are all related and work cohesively for successful implementation. The
framework emerged from the following equation: SI= f (E,C,F), where SI = successful
implementation, E= evidence, C=context, F= facilitation and f= function of.
The first of the 3 components, evidence, is defined as knowledge that supports the
effectiveness of the quality improvement intervention and is a combination of research, clinical
expertise and patient choice. For each of these elements, a range from high evidence that
supports effectiveness to low evidence to support effectiveness may be revealed. For successful
implementation of evidence that supports the intervention a literature search was performed to
find RCTs, systematic review and evidence-based guidelines to support high evidence. There was
also high levels of consensus among clinicians acknowledging that mis-labeling patients as
penicillin allergic is a problem in healthcare and there was a consistency of shared viewpoints

15

regarding the matter. Lastly, patient involvement in the de-labeling process with the allergy
history assessments as well as the evidence to support the many benefits of de-labeling
promoted a sense of partnership with patients.
The second component, context is defined as the environment or setting in which the
intervention is being implemented. Context has been subdivided into three core elements on a
range from low to high: an understanding of the prevailing culture, the nature of human
relationships as summarized through leadership roles, and the organization’s approach to
routine monitoring of systems and services, measurement (Kitson et al., 1998). Using this
ideology, Norton Healthcare was analyzed and found to be a high contextual environment as
evidence by being a patient centered, learning environment with continuing education. Clear
leadership and effective organizational structure that values its employees has been established
with routine monitoring systems, audits and peer reviews.
The final element is facilitation. This is defined as the technique or process used by a person
(i.e., the facilitator) to help others change their attitudes, skills, or behaviors and thereby
improve the likelihood of success of the intervention (Kitson et al., 1998). Facilitators are seen as
people who makes things easier, helps others towards achieving particular goals, encourage
others, and promoting action. In the context of implementing research into practice, the
facilitator’s main job is to help people understand what they have to change and how they
change it to achieve the desired outcome.
Successful implementation is dependent upon the relation between the nature of the
evidence, the context in which the proposed change is to be implemented, and the mechanisms
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by which the change is facilitated (Kitson et al., 1998). This doctoral project was built on
evidence-based practice, emphasizes implementing the intervention and evaluation of the
outcomes while utilizing this framework to drive it toward success.

Review of Literature
Methods of Search

Mis-labeled penicillin allergies currently account for an overwhelming 95% of the total

number of penicillin allergic patients (Blumenthal et al, 2017). Alternative antibiotics used in the
clinical setting of a penicillin allergic patient may be less efficacious and result in suboptimal
outcomes (Stern et al., 2021, Trubiano et al., 2015, Trubiano et al., 2016). Therefore, the Centers
for Disease Control and Prevention and the Infectious Disease Society of America encourages
thorough penicillin allergy history and evaluation outpatient and in an inpatient acute care cite.
The aim of this literature review is to support the implementation of a nurse driven protocol
consisting of an allergy history assessment to help assist with risk stratification and promote
antimicrobial stewardship in the inpatient population.
In the search for literature, CINAHL was used and the word search included: beta
lactam allergy; Penicillin Allergy; intervention; evaluation; de-labeled. The search was restricted
to full text, academic journals in which resulted in 43 studies. The titles and abstracts were
reviewed for relevance, and those that included children or adolescents were excluded. In total
there were 28 articles for full-text review.
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Synthesis of Evidence

Adverse drug reactions affect 10-15% of all hospitalized patients and less than 10% of the

general population (Blumenthal et al, 2017, Fazlollahi et al, 2017, Stern et al., 2021). The most
common drug hypersensitivity identified is an allergy to beta lactam antibiotics or penicillin.
Listed allergies to penicillin and other beta lactams is considered a public health problem if not
100% verified due to the limitations associated with appropriate drug selections and subsequent
increased risk of frequent and longer hospitalization, antibiotic-resistant infections, medical cost
and death (Fazlollahi et al, 2017, MacFadden et al., 2016, Stern et al., 2021, Trubiano et al.,
2015, Trubiano et al., 2016). These allergy documentations are often inaccurate and more so
reflect a common adverse drug reaction or intolerances including diarrhea, nausea, vomiting and
headache as opposed to a true IgE-mediated response (Stern et al., 2021). A documented betalactam allergy increases the use of non-beta lactams such as vancomycin, fluoroquinolones and
other aminoglycosides (Blumenthal et al., 2018). These alternative agents have been associated
with increased cost to the patient, adverse drug events and reduced efficacy in certain clinical
situations (Macy & Contreras, 2014, Krey et al, 2019, MacFadden et al., 2016). A populationbased cohort study found that once a beta lactam allergy was recorded, there was a 14%
increase in mortality risk for patients because they received less effective and/or more toxic
antibiotics for subsequent infections (Blumenthal et al., 2019). The study concluded that the
clinical outcomes for over 30 millions Americans with recorded beta lactam allergies may
improve by proper beta lactam allergy verification and de-labeling. When evaluated properly,
95% of patients with recorded beta-lactam allergies were found to be not allergic (Blumenthal et
al., 2019), (Stern et al., 2021). There are various methods to address inpatient beta lactam
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allergies from the literature. Articles were discovered that discussed a nurse driven quality
initiative intervention that did not show much success or difference in outcomes 3 months
following implementation (Fabre et al. 2020). Although in the first 3 months there was no
improvement, ongoing testing is needed to validate such findings.
Other organizations adapted a pharmacy-driven quality initiative with varying success
rates. Previously, there has been routine penicillin skin testing. Other places utilized routine
allergy consultation, with or without patient screening performed by pharmacist (Blumenthal et
al, 2017). Some organizations have even targeted penicillin allergies only for inpatients with
specific infections or those prescribed specific beta lactam alternative drug therapy such as
Aztreonam (Azactam) (Blumenthal et al., 2017). One study concluded that multidisciplinary
education coupled with pharmacy-led efforts and proper documentation of allergy reaction type
by nursing to confront the challenge of beta lactam allergies among hospitalized patients actually
increased the number of patients that transitioned from non-beta lactam therapy to beta lactam
therapy while inpatient (Krey et al., 2019). A pilot study evaluated the effect of pharmacist driven
allergy interview. Thirty-two patients were interviewed who had a documented beta lactam
allergy. Out of the 32 patients, one-half were found to have reactions consistent with type 1
hypersensitivity and through a thorough medication history, it was found that these patients
have received and tolerated more than 1 dose of a previous beta lactam persuading the
providers to switch them from a non-beta lactam antibiotic to a more appropriate therapy
option with a beta lactam in 26 of the patients interviewed (Sigona et al., 2016). It was
concluded that a pharmacist-driven beta lactam allergy interview was effective in switching
eligible patients to cephalosporin, carbapenem, or penicillin therapy and identifying
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discrepancies between electronic health record (EHR) documented allergies and confirmed
allergies (Blumenthal et al., 2015). Also, the pharmacists’ antimicrobial recommendations were
well received by medical providers, and all patients tolerated the prescribed beta lactam
thereafter (Sigona et al., 2016). One healthcare system adapted a test dose challenge to verify
true allergies. The outcome from this retrospective study increased beta lactam use by 80%
across 5 acute care hospitals in one healthcare system (Blumenthal et al., 2019).
After verification of the existence or not of the allergy, the next step in prescribing beta
lactam therapy becomes updating the electronic health record. Beta lactam allergy relabeling in
the EHR resulted in a significant increase in the percentage of beta lactam antibiotics prescribed
when the allergy label was removed or updated appropriately (Stern et al., 2021, Gaberine et al.,
2020). By de-labeling and updating the EHR judiciously, this will enable the optimization of future
treatment options with first-line therapy and decrease the risk associated with prescribed nonbeta lactams (Shaw et al., 2020).

Identification of Knowledge Gap
In the clinical setting, there is currently no defined procedure or multidisciplinary
process for identifying and evaluating the authenticity of penicillin allergies even though there is
an overwhelming amount of evidence to support such. The purpose of this literature review was
to show that the implementation of a multidisciplinary evidence-based tool to evaluate penicillin
allergies improves patient outcomes and healthcare spending. The intent is to implement a
collaborative, nurse-driven protocol containing an allergy history assessment by utilizing risk
stratification to assist with future evaluation, de-labeling and promote antimicrobial stewardship.
This project could potentially to reduce the redundancy of falsely reported penicillin allergies

20

and diminish the overall use of less efficacious therapy thus decreasing the suboptimal
consequences that follow, improving healthcare utilization and optimizing patient outcomes.

Methods
Project Design
This project utilized a retrospective view into prospective quantitative quasi-experimental
design utilizing an in-person encounter and/or an electronic health record review of patients
who meet inclusion criteria. A two-group pre- and post-intervention sample type was used. If
included in the prospective sample, patients had a penicillin allergy, admitted to an inpatient bed
and were interviewed face-to-face through the admitting nurse or via family member regarding
penicillin allergy reaction history and the answers were recorded in the electronic medical record
with an assessment tool specifically designed with this study in mind. The project also involved a
retrospective electronic health record review of patients who met inclusion criteria. The preintervention period was October 1st, 2021 to December 31st, 2021. The post-intervention sample
was collected between January 11th, 2022 through March 31st, 2022. It was expected that
patients who were admitted to the hospital with a penicillin drug allergy, through the admission
and evaluation process, that at least 90% will have been interviewed with the penicillin allergy
screen in the prospective sample.

Setting
Agency Description. Norton Healthcare not-for-profit hospital and health care system and now
has five adult acute care hospitals and one pediatric hospital. The hospitals provide inpatient and
outpatient general care as well as specialty care including heart, neuroscience, cancer,
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orthopedic, women’s and pediatric services and serves over 600,000 patients annually. A strong
research program provides access to clinical trials in a multitude of areas. The mission and
purpose of Norton Healthcare is to provide quality healthcare to all those that they serve in a
manner that responds to the needs of their community and honor’s their faith heritage. The
vision of this organization is to be the region’s most comprehensive, strongest and preferred
health care organization, setting the standard for quality and caring. At Norton Healthcare, the
values they hold are respect every person, set the standard for quality and caring, continually
improve care and service, demonstrate stewardship of resources, accept accountability of results
and succeed with integrity. This project is aligned with the mission to provide quality healthcare,
Norton’s vision for setting the standard for quality and the values of continually to improve the
care delivered to the patients it serves while demonstrating stewardship of resources.
Stakeholders. For this project, several stakeholders were involved. First, the DNP project will
consisted of Dr. Sheila Melander, the chair, Dr. Jacob Higgins, committee member, Dr. Matthew
Song, the clinical mentor and Dr. Amanda Wiggins, the statistician. In addition, The Norton
Research office had a vested interest in the care of patients participating in clinical research
coordinated with Norton Healthcare. At the clinical sites, various hospital directors agreed to
support the project implementation as well as the nursing educators helped to disseminate the
project information to target nursing staff and providers. Nurses were key participants in
completing the nurse driven protocol. Lastly, but most importantly, the patients were
stakeholders. The patients with a reported penicillin allergy are also considered to be main
stakeholders of this study given they are ultimately going to benefit the most from having
improved outcomes overall.
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Site Specific Facilitators and Barriers. There were several facilitators of completing this project
successfully at Norton Healthcare including leadership and administrative buy-in, ensuring that
the mission, vision and values of Norton aligned with the projects aims, and the availability and
willingness to participate from the bedside staff and providers. The main barriers to
implementation were turnover, employee burnout, reluctancy to participate from staff,
continuity of the study post implementation, as well as continued momentum and compliance.
To overcome these barriers, timely and repeated follow-ups with study personnel, re-education,
quality improvement, as well as the antimicrobial stewardship team were considered for
implementation and evaluation. Ample educational material were prepared and dispersed to the
providers and bedside staff prior and post implementation.

Sample
The sample consisted of adult inpatients who had a penicillin allergy documented on
their electronic health record age 18-99. A sample was collected pre-intervention during the
months of October 1, 2021 to December 31st, 2021. A sample was also be collected post
implementation of the quality improvement intervention during the dates of January 11th, 2022
to March 31st , 2022. Inclusion criteria were patients who had 1) a recorded penicillin allergy, 2)
18 years or older with decision making capabilities or a Power of Attorney/appointed health
surrogate, and 3) admitted to an inpatient bed. Exclusion criteria were 1) no documented
penicillin allergy 2) followed by hospice not seeking curative care, 3) patients who are not in the
general inpatient areas such as OB, Psych, Endoscopy and surgery.
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A sample of 1,456 patients met inclusion criteria from October 1st, 2021 to December 31,
2021 and a sample of 1,472 met criteria from January 11th, 2022 to March 31st, 2022 during the
post implementation period of the intervention to Norton Healthcare.

Procedure
IRB Approval. Prior to the study, University of Kentucky’s Institutional Review Board (IRB)
approval was obtained (eIRB #70486) and approval to conduct the study at Norton Healthcare
from the Norton Research Office (NRO) was obtained. Informed consent was waived for this
study. The first component of data collection was a retrospective chart review and the second
component was a prospective chart review. The healthcare system’s research IT department
compiled a list of medical records meeting inclusion criteria from the system’s electronic
database within the defined timeframes and was then handed over to the primary investigator.
Norton Healthcare Approval. After gaining authorization to carry out the study from the NRO,
the primary investigator (PI) then sought permission to begin the planning phase at Norton
Downtown Hospital from the chief nursing officer (CNO). At the conclusion of the proposed
project presentation, the CNO favored the project idea and requested that it instead be
implemented at the system level. The PI then met with the Norton Healthcare system directors
and educators during an operations meeting. In congruence with the CNO, system leaders
favored the proposed project and gave approval to implement system wide.

Study Intervention. The idea of the nurse-driven protocol was developed based on an integrative
literature review to find affordable, collaborative, practical and effective interventions to address
this large population of patients who have the label of being penicillin allergic. The goal of the
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study team was to ensure the allergy and reaction history on every patient admitted to Norton
Healthcare with a penicillin allergy was obtained and to have the answers readily available to the
clinicians while not adding to the nurses already heavy workload.
To do this, the PI and an Infectious Disease (ID) pharmacist who is a member of Norton’s
Antimicrobial Stewardship Program, worked together over the course of several months. The ID
pharmacist, who is the subject matter expert on antimicrobial stewardship and penicillin
allergies, constructed 8 specific allergy history questions (Appendix A) relating to penicillin to
help differentiate between a true IgE-mediated response and an adverse side effect to penicillin.
Any one of the 8 questions and their answers could potentially assist in leading providers into
making a more informed decision.
The two members of the study team also had several meetings with the Clinical
Informatics Manager of Norton Healthcare to work in collaboration with building the protocol
into the electronic charting system that Norton utilizes called EPIC. During these collaborative
interactions, one of the jobs of the PI was to act as the nurse champion and to find a solution to
the proposed problem of not adding to the nurses workload and ensuring the nurses had to take
no additional steps to complete the questions. By doing this, optimistically, it would promote
compliance from the nurse stakeholders while also guaranteeing an effortless and practical
transition into the implementation of the intervention. The solution was placing this intervention
strategically into the nursing required admission documentation (RAD) inside of the admission
navigator.
The nursing RAD is a list of 26 information gathering points that a nurse must document
on when a patient is admitted to the hospital. These points includes a patient’s past medical and
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social history as well as verification of a patient’s allergies or acknowledgement of no known
allergies. Prior to the intervention, when verifying a patient’s allergies on admission, a nurse had
to confirm or deny the existence of the allergies listed or update the EHR with a new allergy the
patient may report. After a discussion between the study team, it was decided and agreed upon
to build the study intervention into the RAD after the patients allergy verification making it the
27th point of every patient for the nurse to document on.
In addition, the study team also worked in collaboration with the Clinical Informatics
Manager to determine how and where they placed the answers to the questions so that the
answers could both be easily accessible, viewed and documented on if needed by multiple
disciplines to meet all workflows involved in the patients care. After some discussion, the
answers were built into the patients storyboard and designed where if someone was to hover
over a patient’s allergies and the patient was allergic to penicillin, the answers would be revealed
without ever leaving the patients summary page.
The intervention was inclusive of the bedside nurse whose role was to interview the
patient with the aforementioned constructed 8 question intervention (Appendix A) while
documenting the answers appropriately in the EHR on admission to the inpatient setting using
the nursing admission navigator.
The procedure will be as follows:
1. After verifying the patients allergies, the nurse will move forward to the next section
of the navigator titled “PCN Allergy Questions”.
2. One question will be displayed asking if the patient has a penicillin allergy. If the
patient has a penicillin allergy, the nurse must select ‘yes’.
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3. When yes is selected, the remaining list of the 8 research driven questions will be
revealed and cascade down.
4. The nurse will ask the patient the questions and record the answers appropriately in
the EHR.
5. If the patient does not have a penicillin allergy, the nurse will select ‘No’ and no
questions will cascade.
6. Once the questions are answered or the nurse selects ‘No’, the nurse can move
forward to the next section of the navigator. The intervention is complete.
The patients penicillin allergy and the answers to the 8 questions regarding their
reaction only went under review by the provider or pharmacist if clinically indicated.
During the time frame of data collection and thereafter, education was provided to the
bedside nurse and providers regarding penicillin drug allergies and evidence to support delabeling. Nurses were also given education on where to locate the tool in the EHR, indications for
use, and how to complete it. Additionally, providers were delivered separate education on how
to access the answers and resources on next steps. The ID pharmacist participating in the study
made the ID pharmacists at the other 3 adult hospitals aware of the intervention and how to
utilize it.
Demographic measures. For this study, patient’s sex, infection, previous recorded allergy
reactions, previous received antibiotics, allergy reaction comment and deletion comment were
obtained by chart review.
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Data collection. Retrospective and prospective data collection for this study began with
the admission process and EPIC audits/reports on those who have beta-lactam allergies admitted
to inpatient daily during the aforementioned dates. Prospective data collection, post
intervention was followed by the nurses reviewing the allergies during the admission process
with a constructed penicillin allergy history screening tool and the clinicians updating the EHR if
indicated. At the conclusion of the data period, a data request was obtained through the
information technology department of Norton Healthcare. All data was recorded on an excel
spreadsheet and then transferred to SPSS, a data analysis software.
Data Analysis. Descriptive statistics were used when describing the pre- and postintervention samples. Analysis was tailored to the three main objectives of this doctoral project.
After the main objectives were collected and analyzed, additional themes that arose from the
data collected were analyzed further. The chi-square test of association was used to examine
differences in rate of patients who were de-labeled of the penicillin allergy pre-intervention
versus post-intervention. P-values less than 0.05 were considered significant.
Timeline of Project. This doctoral project was completed within a 6-month time frame.
Pre-implementation and retrospective data collection from Norton Healthcare began October
1st, 2021 and concluded December 31st, 2021. Post-implementation and prospective data
collection began January 11th and concluded March 31st, 2022. System education was sent to
providers and nurses at the beginning of January 2022.

Results

The pre-intervention sample population was 1456 patients. Of this sample, 1164 had no
change to allergy status. However, 292 had at least one documentation event after admission
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with 8 patients who had penicillin removed from their electronic health record. Upon chart
review, all 8 patients had true de-labeling occur. Of these 8 patients, 62.5% were females with
the average age being 57.4 years old. Discontinuation reasons consisted of allergy being
miscategorized in 62.5% of patients, erroneous entry for 25% and clinically insignificant in 12.5%.
The post-intervention sample was 1472 patients. Of the post-intervention group, 1229
patients had no change to allergy status or documentation of allergy while 243 patients had at
least one documentation event after admission and 16 of these patients had the penicillin allergy
removed from their electronic health record. After a thorough chart review, it was found that
there were 3 cases where de-labeling did not actually occur. The majority of these patient were
females, 76.9% (n=10) with the mean age of 54.8 years old. Reasons for removal included
clinically insignificant 76.9% (n=10), erroneous entry 7.7% (n=1), and entry miscategorized 15.4%
(n=2).
Therefore, the number of patients from the pre-intervention group (n=8, 0.55%) to the
post-intervention group (n=13, 0.88%) who were de-labeled increased by 62.5%. However, a chisquare statistical test was performed and revealed that there was no statistical significance ( P =
0.28) in the rate of de-labeling.

Allergy removed
Allergy not removed

Pre-intervention
(n = 1456)
8 (0.55 %)
1448 (99.5%)

Post-intervention
(n = 1472)
13 (0.88 %)
1459 (99.12%)

p
(0.28)

Retrospective into Prospective Data Collection
A chart review was performed of those who were de-labeled in both the pre-intervention
and post intervention sample. In the retrospective sample (Appendix B), seven of the eight
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patients had the penicillin allergy removed from their EHR and received antibiotics with 85.7 %
(n=6) receiving penicillin or another beta lactam/beta lactamase inhibitor. Nearly 43% ( n= 3 ) of
patients received one or more type of a first or second generation cephalosporin with 2 patients
overlapping and received a derivative of penicillin in addition to a first and/or second generation
cephalosporin.
Of the post intervention sample (Appendix C), 62.5 % (n=10) received antibiotics.
Penicillin and beta lactams were administered to 30% (n=3) and first or second generation
cephalosporins were given to 10% (n=1).

Nurse Driven Penicillin Allergy Navigator Data
There were 1131 interactions with the penicillin allergy navigator. Nurse compliance was
76.9% (n=1472). Of those screened, 51.5% (n=582) had complete documentation. Of the
patients who the screening was attempted, 90.9% (n= 1028) answered yes to having an allergy
while 8.5% (n= 6) answered no and 0.6% (n= 7) had no answer selected but did have further
questions completed in the screening. Nearly 52% answered that their reaction was greater than
10 years ago, 14.5% answered their reaction was less than 10 years ago. When asked if the
reaction happened after the first dose 27.6% answered yes and 5.8% indicated no. Nine and a
half percent stated their reactions started after several doses and 17.8% stated it did not occur.
Study participants were asked if their reaction required hospital or ED care and 17.2% said yes
and 19.9% said no. Six and a half percent of people reported needing treatment with
epinephrine while 21.4% denied. When asked if they had taken Amoxicillin since reaction
without issue, 108 patients said yes and 148 said no. When they were then asked if they have
taken Keflex without issues since, 124 said yes and 107 said no (Table 1.).
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Discussion
Retrospective and Prospective Rate of De-labeling
In this project, there was not an intervention put into place that proactively sought out
patients to de-label. Therefore, even though the absolute values were low, there was nearly a
63% increase from the pre to post intervention groups for patients who were de-identified as
penicillin allergic (0.55% vs 0.88%, p= 0.28). Given the similar size of the sample groups and
previous de-labeling patterns within the system, it was determined that this was an
improvement, however not statistically significant. Additionally, there was no way of knowing for
certain if the nurse-driven assessment was the reason for the increase for the de-labeling or if
this was simply by chance.

Retrospective Chart Review
The retrospective chart review revealed multiple themes. The breakdown of each
individual de-labeling cases can be found in Appendix B. First, nurses were the primary discipline
to remove the allergy from the EHR in 5 out of the 8 cases identified, however not on admission
to the hospital. In two of the patient cases, the allergy was removed by an infectious disease
physician while reviewing allergies and previous tolerated medications when deciding
antimicrobial choices.
This review also supported that updating the chart timely and providing adequate
education to the patient until learning is achieved regarding their allergies and removal is
essential for the healthcare process. In one case of de-labeling in the retrospective group, a
patient had a known MSSA infection with a penicillin allergy documented in 2012 (Appendix B.6).
The allergy history events show that this patient’s allergy to penicillin was re-added twice and
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removed three times over the span of five months by multiple different disciplines, inpatient and
outpatient, on the healthcare team. An inpatient pharmacists attached the comment “Tolerates
Nafcillin” after the patient tolerated a Nafcillin graded dose challenge led by infectious disease
while admitted with MSSA bacteremia. However, the allergy was not removed from the chart
until nearly a month later by another inpatient pharmacists. A primary care provider (PCP)
readded and removed the allergy in the same day nearly two months following when the patient
was seen for outpatient follow-up. Thus, it could be the case that the PCP saw the comment
from the IP pharmacist attached to the allergy, therefore it was removed again. In the coming
months, the patient was readmitted with recurrent MSSA bacteremia where the allergy was readded by the nurse on admission. The patient was placed on empiric IV Cefepime and
Vancomycin for initial treatment. The allergy went under review by the ID physician, removed for
the third time and the patient was de-escalated to first line therapy with IV Nafcillin. The allergy
being re-added by the PCP and a nurse leads one to believe that this patient may still be
reporting that they have a penicillin allergy. This brings into question whether or not the patient
was made aware that their allergy had been disproven and removed from their health record or
if the patient understood what tolerating the Nafcillin graded dose challenge meant during their
initial admission. This supports the notion that patient education in the event of allergy delabeling is crucial.
Secondly, 4 cases were identified to have been de-escalated from broader spectrum
therapies and switched to first line treatment with a first generation cephalosporin or betalactam (Appendix B.1, B.6, B.7, B.8) In 3 of the 4 cases of appropriate antibiotic administration,
de-escalation only occurred only after the penicillin allergy was disproved or removed via chart
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review. Also, a chart review of previous tolerated medications and reactions was documented to
have occurred at some compacity and played a role in 4 of the 8 patients de-labeled proving that
a multimodal approach via patient interview, thorough chart review and appropriate
documentation is essential for de-labeling (Appendix B.1, B.2, B.6, B.8), (Stern et al., 2021,
Gaberine et al., 2020, Shaw et al., 2020).
Lastly, 3 of the 8 cases of de-labeling was initiated and ultimately occurred because of
the nurses discovery with their patient questions and appropriate documentation when verifying
allergies (Appendix B.2, B.3, B.7) The first of the three involved an erroneous entry (Appendix
B.7). The nurse noted in the chart, “Caregiver states was a mistake when entered” and removed
the allergy from the EHR. Patient was initially started on empiric coverage for HCAP with a third
generation cephalosporin and azithromycin. Upon review, the ID pharmacists recommended to
de-escalate the patient to ampicillin-sulbactam in which the provider accepted the
recommendation.
The second de-labeling initiated from a nurse inquiring about what type of reaction the
patient had when exposed to a penicillin (Appendix B.3). The nurse documented dermatitis and
the allergy occurred in the patients childhood. Some months later this patient had a complicated
hospital course involving multiple surgeries and an intrabdominal abscess. The patient
underwent an ampicillin dose challenge which was well-tolerated thus the allergy was removed
by the nurse. To finish, a patient had a penicillin allergy noted with the reaction of hives
occurring in childhood. On a subsequent admission, a nurse removed the allergy after noting
that the patient had taken penicillin and amoxicillin since with no adverse events (Appendix B.2).
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These cases highlight the invaluable role at the bedside the nurse plays and their ability to use
clinical judgement.

Prospective Chart Review

The prospective chart review revealed multiple themes as well (Appendix C). First, there

was a more multidisciplinary involvement in the de-labeling process involving the pharmacists,
nurses and providers. Pharmacist were actively involved in 5 of the patient cases where delabeling occurred compared to 2 in the pre-intervention sample. Their involvement included
antibiotic recommendations for de-escalation, graded dose challenges, removal of allergies and
updating allergy comments.
During the chart reviews, it was found that 10 of the nurse driven penicillin allergy history
screens were used correctly, 3 were not and 3 were not able to be reviewed. Two patients
received a graded dose challenge while one was directly in result of the nurse screening tool and
the patient was ultimately de-labeled of their allergy. In an interesting scenario, a nurse added a
penicillin allergy to the patients’ medical record and moved forward to the nurse-driven tool to
inquire deeper about the patient’s reaction to penicillin (Appendix C.7). This nurse then asked
the patient the first three questions before returning to the allergy tab to delete the penicillin
allergy that the nurse just added, marking it an erroneous entry. It is uncertain to know, but the
allergy history questions may have prevented this patient from being labeled with a penicillin
allergy. In another situation, a nurse was verifying allergies with a patient and their family
member who denied the patient of having the penicillin allergy (Appendix C.4). The nurse
entered a comment attached to the allergy and stated “Father at bedside said he does not
believe patient has this allergy, “ then removed the allergy from the EHR. The nurse went
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forward to the allergy questions, selected no and enter a comment that stated, “Father denied
history.” This nurse completed the screen and allergy verification appropriately.
In all three cases where the screen was not completed correctly, additionally, these cases
were situations where true de-labeling did not occur. For instance, during admission, a nurse readded a penicillin allergy to a patients record with the patient reaction comment of, “Pt
reported, not sure but ‘could kill me’”. Upon review by the ID pharmacist, the allergy was
removed due to the fact that it originally was removed on 6/30/2021 concluding that it was
erroneously re-entered back by the nurse. It’s safe to assume during the admission process
when the nurse was verifying allergies, the patient may have stated they had a penicillin allergy
and requested it to be added back to their medical record. If this did occur, again, it supports
that patients need thorough education and to be informed when their allergies are disproven
and removed from their medical records.
Another interesting situation that was discovered was a patient was admitted after
experiencing hypoxia and suspected anaphylactic shock after receiving their first dose of
amoxicillin outpatient. The allergy to amoxicillin and penicillin was added to the EHR on
admission day (1/10/2021) by the pharmacist. Two days after admission the nurse removed the
penicillin allergy after speaking with the attending provider and commented, “Spoke with Dr. …..
and patient has received amoxicillin and penicillin several times in his life.” Even though the
nurse removed the penicillin allergy, the allergy to amoxicillin remained on the EHR with the
comment added from the pharmacist, “PCN anaphylaxis entered for hypoxia while patient was
exposed to PCN-agent. Per Dr. ……, patient confirmed he has taken amoxicillin/Augmentin
multiple times in the past without issue. Provider believes multiple other medical issues could
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have contributed to episode of hypoxia (CHF EF =20, COVID pneumonia) and this is an unproved
PCN allergy.” As a result, this patient was not truly de-labeled of the penicillin allergy and would
more than likely benefit from undergoing further review.
In this sample, there was 1 case of antibiotic de-escalation from piperacillin/tazobactam
to Amoxicillin-clavulanate in a patient who was found to have an intraabdominal abscess
(Appendix C.1). In 7 of the de-labeled patients, it was documented that the patient had received
penicillin or a derivative since initial reaction through a chart review or patient interview
(Appendix C.1, C.2, C.3, C.5, C.6, C.8, C.13) .
In 7 of the 13 patients with the allergy removed in this sample, again de-labeling was
initiated and ultimately occurred because of the nurses discovery with their patient questions
and documentation when verifying allergies (Appendix C.1, C.3, C.4, C.6, C.7, C.8, C.12). For
example, a nurse removed an allergy on 3/23/22 after recognizing the patient was not allergic to
penicillin following reviewing the allergy comment left by a previous nurse added on 6/18/2014
stating, “Takes amoxicillin without issue”. Thus, the nurse recognized that this patient was not
allergic to penicillin and removed the allergy marking it as miscategorized. Comments left by
nurses upon allergy verification were found in to 10 of the 21 de-labeling events in the overall
study, or 47.6%. This is nearly half of those who were de-labeled demonstrating that the nurses
job at the bedside is pivotal in de-labeling these patients and promoting antimicrobial
stewardship.
There were also missed opportunities of timely de-labeling present throughout both
samples. In the pre-intervention group, there were 2 missed opportunities to remove the allergy
(Appendix B.6, B.8). In both cases, the allergy was updated that the patient tolerated a similar
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agent that disproved the allergy existed from an ID physician and a pharmacist. However, the
allergy was not removed from the EHR until later. In the post-intervention sample, there were 3
patient cases where de-labeling could have occurred sooner and 6 missed opportunities total
(Appendix C.1, C.3, C.6). One patient review revealed 3 missed opportunities for de-labeling over
the span of 4 years. Shaw et al. (2020) emphasized the importance of de-labeling and updating
the EHR timely to ensure the optimization of future treatment options with first-line therapy and
decrease the risk associated with prescribed non-beta lactams
Patients with a penicillin allergy also have higher likelihoods of developing hospital
acquired infections (HAIs) (Chua et al, 2020). Of those de-labeled pre- and post-intervention, 7
patients total had a current or history of an HAI such as C diff, VRE, CRE and/or MRSA supporting
the literature that these patients are at higher risk for adverse events and outcomes thus the
manner in which we need to be de-labeling patients should be pro-active, not re-active.

Nurse Driven Penicillin Allergy History Navigator
Even though compliance to the nurse-driven navigator was not 100%, nurses were still
able to gather valuable data on patients admitted with a penicillin allergy at a rate that a
pharmacist or a physician could not. A main goal of the study team was to fill the gap of
resource limitations associated with penicillin allergy de-labeling and transform it into a
collaborative approach by utilizing nurses. In a nearly a 3-month period, nurses completed 1,131
focused patient interviews involving penicillin allergies (Table 1). Future studies would have to be
completed to determine. The question then becomes ‘is quality more important over quantity’.
Yes, nurses interacted with the navigator 1 131 times, however, how many of these times are
actually influential in penicillin allergy de-labeling. It is uncertain to know if the physician or
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pharmacists were the one conducting the interviews, if they would have received different
answers.
Each question was selected to carefully assess a patients history to identify potential risk,
the first step in allergy de-labeling. Chua et al. (2020) conclude that over 80% of patients lose
their sensitivity to the penicillin allergy after a decade. The navigator collected that 587 patients
stated that their reaction was greater than 10 years prior. Using this benchmark, this could very
well mean these patients have a lower risk for having a response if expose to a penicillin.
When asked if patients have received amoxicillin since initial reaction without issue, 108
patients answered yes. In the retrospective and prospective chart reviews above, patients were
de-labeled by reviewing previous medications and verifying this alone. A question about
cephalexin was asked, a first generation cephalosporin. One-hundred and twenty-four patients
answered yes that they have received this medication since their initial reaction. Typically,
patients who have a true penicillin allergy cannot receive first or second generation
cephalosporins due to very low but present risk of cross-reactivity. These patients are more likely
to receive third and forth generation class therapy. The relevance of this question becomes if a
person can tolerate a first generation cephalosporin like cephalexin, which cross chains are
almost identical to that of a penicillin, then they also, almost all the time, can tolerate penicillin.
Next, a question was asked to assess whether a true IgE-mediated response occurred.
The question read, ‘Did your reaction happen after the first dose’, 312 patients answered yes
while 66 patients answered no. A true IgE-mediated response typically happens within 15
minutes of being exposed to the allergen, however, not always. A second question was asked,
did your reaction happen after several doses. This question was used because sometimes a IgE-
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mediated response does not occur until the second exposure when the body has created the
IgE-antibodies and is exposed to the allergen again. Interestingly, 107 patients answered yes that
their reaction happened after several doses and 201 patients replied no.
A question to assess the type of reaction they had was asked by the nurse (Table 1.) .
Some of the answers do not imply a IgE mediated response. Of those interview, 24 patients
reported a non-itching rash and 33 patients answered yes to nausea, vomiting and diarrhea.
These reactions historically are intolerances and adverse reactions to the antibiotics, not an
allergic reaction.
By using the answers to these questions, the nurse was able to collect data on a large
sample of patients that provided insight to the clinicians on the risk value associated with the
patient and their potential reaction to receiving a penicillin. This tool also was able to gather this
data on over 75% of patients who were admitted to Norton with penicillin allergies during the
specified time frames far surpassing previous efficiency. Further integration of this tool into
practice with enhanced teaching for the nurses could have a major impact on outcomes both
short term and long term.

Next Steps
This tool is now being used as a standard of practice at Norton Healthcare. The outcomes
and rate of de-labeling will be followed as it is further integrated into practice. Furthermore, new
ideas developed following this project will be presented to the stakeholders.

Implications for Future Practice

The implications for future practice are boundless. First are the implications involving an
antimicrobial stewardship program (ASP). In a formal ASP, the recognized major stakeholders
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include the pharmacy, an infectious disease physician, infection prevention personnel,
epidemiology or microbiology professionals, and administrative support. By nature, antimicrobial
stewardship is multidisciplinary and interesting enough, the only gear that seems to be missing
from this clinical machine are nurses. When in actuality, it is the nurse that is the connection
between these disciplines and the patient.
Nurses already contribute to the goals of ASPs effectively in our daily nursing practice.
For instance, when cultures are ordered or when a standing protocol is in place, early collection
of specimens are almost always collected by the nurse. Many of these test have nursing standing
orders attached and allows the nurse to use their clinical expertise and judgement to initiate.
Furthermore, it is the nurse who often times recognizes the first signs of infection to initiate the
order and bring them to the attention of the provider. As highlighted, the nurses role in
documentation and verification of allergies in our daily practice aligns with that of ASPs. Many
daily activities of the nurses overlap with those of the traditional ASP stakeholders. Therefore, a
future implication of practice could be finally recognizing the nurse as a valuable member of the
ASP organizational chart and creating a nurse champion to truly make it multidisciplinary,
effective, efficient and safe for patient care.
A second implication involving the ASP is implementing routine utilization of an Allergist –
Immunologist (AI) for inpatients on a needs-base only such as those identified to be high risk of a
reaction by this tool or if not enough information can be provided from the EHR or patient
interview to make a determination. This nurse-driven protocol was able to collect allergy
histories on patients and the answers could be used to evaluate the potential risk of mild to
severe type 1 IgE-mediated reactions if re-exposed. By utilizing the nurses routine position in
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patient care to collect this history instead of the AI, it potentially saves time allowing the AI to be
more productive and review more patients. The AI could review the answers along with the
medical record and only interview the patient if needed to make an informed recommendation
on how to proceed with allergy testing. Similar to staff nurses, AIs are often overlooked but
nonetheless an invaluable asset to ASPs. In this implication, the tool not only assists in valuable
data collection but also assisting in appropriate allocation of resources.
Another major implication for future practice with this tool is expanding it to other areas
of the hospital and community. This nurse-driven protocol was only used in the acute general
inpatient setting meaning it excluded all outpatient services such as pre-admission testing (PAT),
immediate care centers and primary care offices. It also excluded areas in the hospital such as
endoscopy, interventional cardiology/Cath lab, pre-op, labor and delivery, mother/baby and
surgery. Surgery areas in particular would benefit from utilizing this tool considering first
generation cephalosporins are first line therapy in surgery prophylaxis to decrease SSIs. Including
this tool as a part of a patient’s PATs and based on their answers, placing a referral for an oral
dose challenge, skin test or directly de-labeling prior to surgery, could lead to an overall the
decrease in adverse events such as SSIs, reduced cost and optimizing patient surgical outcomes.
However, when expanding to other areas, a facilitator is recommended to educate and drive the
protocol to enhance compliance.
The opportunities with education also come with no limits. The need for education was a
theme in the chart reviews and well as when reviewing navigator data. Educating the nurse
stakeholders, as the hub of communication between the interdisciplinary team, to know the
difference between an adverse effect verses a true IgE- mediated response such as a
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maculopapular rash versus hives and cross-reactivity agents enhances the nurses ability to
advocate, explore the reaction history more in depth and document appropriately. It is in a
nurses daily workflow to verify and acknowledge medication allergies, and yet we are the
discipline that are educated the least about them. It is essential for optimizing patient care to
educate nurses about medication allergies, what true allergies entail and how to differentiate
between the two. If a guideline or reference can be created and placed within the protocol along
with ample education delivered, the bedside nurse could make an informed decision regarding
whether there is enough information gathered for the allergy to be reviewed for removal. If so,
the nurse could proactively initiate and send a pharmacy consult to review the allergy, and if in
congruence with the nurses judgement, the allergy could possibly be removed by the pharmacist
or could go under further review.
Educating the patient as the key stakeholder is also a future implication for practice.
Patients should be educated regarding the penicillin allergy, be adequately informed when it is
determined to no longer be clinically significant and the evidence to support such determination
be explained to them until adequate knowledge has been achieved. There were multiple
instances where a patient was de-labeled of the penicillin allergy, discharged home and on a
subsequent admission the allergy was added back on the patients request. The need for
education among the patients is arguably the most important because they are the ones who
have the most autonomy over their own healthcare. Thus, it is crucial to educate them when an
allergy has been disproved and is removed.
As stated previously, a medication allergy verification is collected on admission to the
hospital by the nurse. This is already a function of ASP and is accepted widely as the nurses
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responsibility. Furthermore, this study’s nurse driven protocol to assess a patient’s penicillin
allergy history is a function that aligns with the goals of the ASP. If a penicillin allergy has been
documented, the subsequent consequences are routinely linked to the members of the ASP
team including pharmacy, microbiology, infectious disease, and fiscally to the hospital
administration. A future nursing implication could be to also assess a patients medication history
and have this built into this tool. This will pull the history of medication usage from the EHR into
the protocol for the nurse to review all potential cross-related antibiotics that the patient may
have had received. This could become a worthwhile element in the event of penicillin allergy
verification and a mode to assist in de-labeling.
Another implication is utilization of this tool and the data gathered in collaboration with
the multidisciplinary team, ample educational, physical resources and providing available
personnel, to work together to implement a proactive interventional multi-modal approach led
by the ASP involving penicillin skin testing and/or challenge dosing to de-label the low-risk
patients identified as penicillin allergic.
The tool is multifaceted, it has both a short-term impact and can influence long-term
outcomes. The final future nursing implication is to follow and track these outcomes over time to
measure the influence of this nurse driven tool in this patient population and healthcare system.
These outcomes include overall healthcare utilization, readmission rates, hospital acquired
infections, the occurrence of resistant bacteria, rate of de-labeling, antimicrobial use and
following the trend of each hospitals antibiograms.
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Limitations
Throughout implementation of this quality improvement intervention, many limitations
presented themselves. First, due to the overwhelming size of this project and the location of
multiple sites, it was difficult to facilitate compliance without having a focused facilitator at each
site overseeing and performing feedback audits. Additionally, when dealing with multiple sites,
dispersing the education and assessing for achieved learning outcomes of what is being asked of
nurses or the need for further teaching was impossible to measure. Nurse turnover and burnout
proved to have its impact on compliance secondary to the overwhelming staffing ratios with
their patient loads in addition to the interchange of travel nurses that may not have received the
initial or follow up education.
Also, the primary investigator was informed that in the middle of post-intervention time
frame, one of the four ID pharmacists left their position at the hospital and the responsibility of
that hospital was being spilt between 2 of the other ID pharmacist in addition to their own
increasing their workload.
Time limitations also came about. To brainstorm ideas, present the idea, gain support,
develop a plan of action, and collaborate with multiple disciplines to build this protocol into the
EHR to become system wide took nearly eight months delaying the start of the project and
limited the prospective time frame, thus not allowing for an equal time of three months for
retrospective and prospective data collection. Lastly, data extraction was a limitation due to the
multitude of ways a penicillin could be stored in the EHR and the ability to extract the sample.
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Conclusion
To summarize, a nurse-driven protocol was designed, built into the EHR, and
implemented across Norton Healthcare covering 1,607 beds. The assessment was used by every
nurse working in the inpatient area and reviewed by members of the multidisciplinary team. This
was achieved by gaining support from the systems administration, collaborative efforts with the
multidisciplinary team and acquiring interdisciplinary buy-in. It is worth mentioning that this is no
longer a pilot study but is now a standard of practice. The nurse allergy assessment continues
after this study has concluded.
Although it is impossible to know if patients were de-labeled from the assessment alone,
this study exemplified what successful collaboration within a multidisciplinary team to solve a
problem could do. The ability of the nurse to assess the allergy history of patients allergic to
penicillin at the rate they did far surpasses the ability of a single pharmacist or physician. The
next steps towards success would be further educating the nurses and working closely with
Norton’s ASP to improve this tool, the functionality and to unlock the nurses potential while
defining and expanding their role within an antimicrobial stewardship program.
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Table 1. Nurse Driven Penicillin Allergy Navigator Data
Question
Penicillin Allergy?

When was your reaction?

Did your reaction happen after the
first dose?

Did your reaction happen after several
doses?

Did your reaction require ED or
Hospital Care to treat your reaction?

Did your reaction require treatment
with epinephrine?

Have you taken Amoxicillin (AMOXIL)
or amoxicillin-clavulanate
(AUGMENTIN) without issue since?

Have you taken cephalexin (KEFLEX)
without issue since?

Reaction?

(n=1131)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Yes- 90.9% (1028)
No- 8.5% (96)
NULL- 0.6% (7)
Greater than 10 years ago- 51.9% (587)
Less than 10 years ago- 14.5% (164)
NULL- 33.6% (380)
Yes-27.6% (312)
No- 5.8% (66)
Do not Know- 32.1% (363)
NULL- 34.5% (390)
Yes- 9.5% (107)
No – 17.8% (201)
Do not know- 36.9% (416)
NULL- 36% (407)
Yes- 17.2 (194)
No- 19.9% (225)
Do not know 27.9% (315)
NULL- 35.1% (397)
Yes- 6.5% (74)
No- 21.4% (242)
Do not know- 36.4% (412)
NULL- 35.6% (403)
Yes- 9.5% (108)
No- 13.1% (148)
Do not know- 36.2% (409)
NULL- 34.5% (390)
Have not taken since- 6.7% (76)
Yes- 11% (124)
No- 9.5% (107)
Do not know 39.3% (444)
NULL- 34.8% (394)
Have not taken since- 5.5% (62)
(Most Prevalent selections, not all inclusive)
Selections including Anaphylaxis- 11.5% (123)
Hives- 16.4% (186)
Hives, Itching rash- 2.7% (30)
Itching Rash- 11.6% (131)
Lip Swelling- 1.9% (22)
Nausea, vomiting or diarrhea- 2.9% (33)
Non-itching Rash- 2.1% (24)
Shortness of Breath- 2.4% (27)
NULL- 29.9% (338)
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Appendix A. Focused Allergy History Questionnaire
1.

Penicillin allergy?
a)

2.

Yes

b) No

What was your reaction? (select all that apply)
b)

Other

b) Anaphylaxis

c) Shortness of Breath d) Diarrhea

e) Itching

f) Photosensitivity g) Nausea and Vomiting h) nausea only

i) Swelling

j) Anxiety k) Palpitations l) Dermatitis m) Rash n) Tinnitus

o) GI Bleeding p) Hemorrhagic Stroke q) GI Intolerance r) Cough
s) Headache t) Dizziness u) Hallucinations v) Fever w) Wheezing
x) Runny Nose y) Angioedema
3.

When was your reaction?
c)

4.

Did your reaction happen after the first dose?
d)

5.

Yes b) No c) Do not know

Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate (AUGMENTIN) with no issue since?
h)

9.

Yes b) No c) Do not know

Did your reaction require treatment with epinephrine?
g)

8.

Yes b) No c) Do not know

Did your reaction require ED or hospital care to treat your reaction?
f)

7.

Yes b) No c) Do not know

Did your reaction happen after several doses?
e)

6.

Less than 10 years ago b) Greater than 10 years ago

Yes b) No c) Do not know

Have you taken cephalexin (Keflex) with no issue since?
i)

Yes b) No c) Do not know
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Appendix B. Retrospective Chart Review
B.1 Patient 1. TV MSSA Endocarditis
Penicillin allergy entered 12/20/2016
IV Cefazolin
IV cefazolin deescalated to IV nafcillin 10/19/2021 after documenting the patient tolerated Amoxicillin
in note
Removed by ID Physician 10/21/21
“Pt is tolerating nafcillin without problem”
Entry miscategorized as an allergy

B.2 Patient 2. GBS
Penicillin allergy entered 9/25/21
Hives, “was told she had allergy as a child, has tolerated previously”
Removed by nurse 11/12/21
“pt has taken pcn and amoxicillin with no adverse events”
Penicillin G
Entry miscategorized as an allergy

B.3 Patient 3. RUQ abscess/complicated surgery course
Penicillin allergy entered 9/3/2020
“unsure of reaction”
RN updated reaction 3/10/21
Dermatitis, “CHILDHOOD”
Complicated surgery course
Ampicillin graded dose challenge
Removed by nurse 11/30/2021
Entry miscategorized as an allergy
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B.4 Patient 4. Unknown
Reported patient does not know reaction
Removed with comment “pt reports no longer allergic as a child and no longer experiences reaction”
Augmentin
Entry miscategorized as an allergy

B.5 Patient 5. Suspected DM foot OM
Penicillin allergy entered 12/14/21
Allergy removed by nurse 12/14/21
Began IV Pipracillin/tazobactam
Entry miscategorized as an allergy

B.6 Patient 6. Recurrent MSSA bacteremia with lumbar discitis, osteomyelitis, intradiscal abscess
Penicillin allergy entered 5/30/2012
Rash, Hives
Allergy updated by IP pharmacist  6/15/21
“Tolerates nafcillin” after undergoing nafcillin graded dose challenge for MSSA septicemia while IP
Allergy removed by IP pharmacist 7/6/21
Added and removed by PCP 9/9/2021
Erroneous Entry
Re-added by RN on admission  11/19/2021
IV cefepime/Vancomycin for MSSA bacteremia
Allergy deleted by ID Physician 11/20/2021
“Will remove allergy. Please do not re-add allergy unless there is new evidence of a hypersensitivity
reaction”
IV cefe/vanc deescalated IV Nafcillin
Entry miscategorized as an allergy: Tolerates nafcillin without issues
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B.7 Patient 7. HCAP, Intrabdominal abscess
Penicillin allergy entered 5/19/2019
Hives
Admitted to HCAP/Sepsis
Removed by nurse on admission 11/26/2021
“Caregiver states was mistake when entered”
Erroneous entry
Began IV azithro/cefe for HCAP 11/26/2021
ID pharmacist recommended to deescalate to IV unasyn 11/30/2021
Accepted

B.8 Patient 8. CAUTI (late in admission)
Penicillin allergy added by MA  11/8/21
ID physician updated allergy 11/11/21
“Pt tolerate Augmentin 10/2021”
Removed allergy by nurse on admission 12/3/2021
Erroneous entry
CAUTI late in admission 12/18/2021
Start IV Ceftriaxone
Culture: Proteus mirabilis
IV Ceftriaxone transitioned to Cephalexin
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Appendix C. Prospective Chart Review
C.1 Patient 1. Persistent intra-abdominal abscess 2/2 Chrons Disease, sepsis
Penicillin allergy added by Nurse 2/15/2018
Nurse updated allergy comment 8/27/2020
“Rash on face”
Nurse updated allergy 12/21/2021
“Rash on face, Pt comments she got this from oral PCN not IV PCN”
ID Pharmacist updated allergy 1/4/2022
“Rash on face, Pt comments she got this from oral PCN not IV PCN. Tolerated pip/tazo during 1/3
admission”
Admitted with a recurrent intra-abdominal wall abscess 2/3/2022
Nurse Screening questions √
Removed by ID physician 2/7/2022
Entry determined to be clinically insignificant
Empiric coverage with IV pip/tazo de-escalated to Augmentin on DC
Screening questions:
Penicillin Allergy?
What was your reaction?
When was your reaction?
Did your reaction happen after the 1st dose?
Did your reaction happen after several doses?
Did your reaction require ED or Hospital Care to treat your reaction?
Did your reaction require treatment with epinephrine?
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate (AUGMENTIN)
without issue since?
Have you taken cephalexin (KEFLEX) without issue since?

C.2 Patient 2. Unknown
Recorded reaction comment
“Anything affiliated with Penicillin as well”
Allergy removed with comment
“Pt tolerated amp/sulbactam Jan 2022”
Entry determined to be clinically insignificant
Screening questions:
Unknown
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Yes
Hives
—
—
—
—
—
—
—

C.3 Patient 3. Diabetic OM
Penicillin allergy added by podiatrist4/1/2015
Reaction: Shortness of breath
Nurse updated allergy comment 11/9/2019
“Pt states he has had forms of PCN and done fine”
Doctor updated allergy comment 11/15/2020
“Pt states he has had forms of PCN and done fine. Reports reaction to penicillin was as baby”
Admitted for L foot wound 3/2/2022
Nurse Screening questions √
3/2/2022Admitting NP note states,
“pt does have recorded pcn allergy but per pt he has since tolerated PCN”
Empiric coverage with IV Vanc/Cefe
Allergy deleted by ID physician 3/3/2022
“He got penicillin in the hospital 3 years ago, per patient and his wife, and had no reaction. Original
reaction was as an infant, he does not recall.”
Entry determined to be clinically insignificant
DCIV Vanc/Cefe, appropriate for culture
Screening questions:
Penicillin Allergy?
Yes
What was your reaction?
Anaphylaxis
Greater than 10
When was your reaction?
years ago
Did your reaction happen after the 1st dose?
Yes
Did your reaction happen after several doses?
No
Did your reaction require ED or Hospital Care to treat your reaction?
Do not know
Did your reaction require treatment with epinephrine?
Do not know
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate
Do not know
(AUGMENTIN) without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
Do not know

C.4 Patient 4. Intracranial hemorrhage
Penicillin allergy added by nurse  10/24/2012
Removed by nurse on admission 3/10/2022
Nurse Screening questions √
“Father at bedside said he does not believe patient has this allergy”
Entry miscategorized as an allergy
Screening questions:
No. The
comment is
Penicillin Allergy?
according to
father NKA.
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C.5 Patient 5. Neurosyphilis
Penicillin allergy added 9/12/2016
DA from ID office for PCN desensitization 3/9/2022
Nurse Screening questions √
ID pharmacists reviewed patient and recommended graded dose challenge
(Did not use history questions from nurse screen)
Underwent penicillin desensitization and tolerated
Allergy removed by ID Pharmacist 3/10/2022
Entry determined to be clinically insignificant
Screening questions:
Penicillin Allergy?
What was your reaction?

Yes
—

When was your reaction?

Less than 10
years ago

Did your reaction happen after the 1st dose?

Do not know

Did your reaction happen after several doses?

Do not know

Did your reaction require ED or Hospital Care to treat your reaction?

Do not know

Did your reaction require treatment with epinephrine?

Do not know

Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate (AUGMENTIN)
Yes
without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
Yes
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C.6 Patient 6. Cervical Spinal Stenosis
Penicillin allergy added by APRN 2/19/2013
“STATES SAW SNAKES AS A CHILD DURING COURSE OF RHEUMATIC FEVER FOLLOWING INFECTION.”
Allergy comment updated by APRN 6/18/2014
“Takes Amoxicillin without issue”
Admitted to hospital for scheduled surgery
Allergy reviewed by nurse
Nurse Screening questions √
Allergy removed by nurse on admission 3/23/2022
Entry miscategorized as an allergy
Screening questions:
Penicillin Allergy?

No
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C.7 Patient 7. Acute Pharyngitis
Penicillin allergy added on admission 3/9/2022
Reaction: Itching
Nurse Screening questions √ (1)
Nurse returned to allergy, deleted 3/9/2022
Erroneous entry
Return to nurse screening questions to edit (2)
Screening questions:
(1)
Penicillin Allergy?
What was your reaction?
When was your reaction?
Did your reaction happen after the 1st dose?
Did your reaction happen after several doses?
Did your reaction require ED or Hospital Care to treat your reaction?
Did your reaction require treatment with epinephrine?
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate (AUGMENTIN)
without issue since?
Have you taken cephalexin (KEFLEX) without issue since?

(2)

Penicillin Allergy?
What was your reaction?
When was your reaction?
Did your reaction happen after the 1st dose?
Did your reaction happen after several doses?
Did your reaction require ED or Hospital Care to treat your reaction?
Did your reaction require treatment with epinephrine?
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate (AUGMENTIN)
without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
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Yes
Itching rash
Less than 10
years ago

No
—
—
—
—
—
—
—
—

C.8 Patient 8. GIB
Penicillin allergy added on admission2/19/2022
Admitted with GIB & liver failure  2/19/2022
Nurse Screening questions √
ID Pharmacist reviewed allergy and answers to nurse screening questions
Underwent graded dose challenge with pip/tazo 2/28/2022
Tolerated
Allergy removed by ID pharmacist 3/1/2022
“Pt reports tolerating amox-clav since reaction to penicillin and has tolerated pip/tazo during March
2022 admission”
Entry determined to be clinically insignificant
Screening questions:
Penicillin Allergy?
Yes
No
What was your reaction?
—
—
Greater than
When was your reaction?
10 years
—
ago
Did your reaction happen after the 1st dose?
No
—
Did your reaction happen after several doses?
Do not know —
Did your reaction require ED or Hospital Care to treat your reaction?
No
—
Did your reaction require treatment with epinephrine?
No
—
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate
Yes
—
(AUGMENTIN) without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
Yes

C.9 Patient 9. Unknown
Penicillin allergy added with comment
“Never taken it but my entire family is allergic to it. Rash and anaphylaxis”
Allergy removed with comment added
“Family history is not associated with risk of an individual's sensitivity and guidelines recommend not to
avoid beta-lactams or penicillins due to family history.”
Entry determined to be clinically insignificant
Screening questions:
Unknown
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C.10 Patient 10. MSSA IE, Septic embolic infarcts
Patient admitted w/ Acute CVA 2/2 septic embolic infarcts from MSSA IE 1/29/2022
Nurse Screening questions √ 1/29/2022
Penicillin allergy added by nurse following receiving IV Nafcillin1/31/2022
“Nausea and vomiting”
Allergy removed by IP pharmacist 2/2/2022
“Patient actively receiving and tolerating nafcillin, a penicillin antibiotic. GI side-effects are not allergic
reactions. Please do not re-add allergy unless there is new evidence of a hypersensitivity reaction.”
Entry determined to be clinically insignificant
Nurse Screening questions √ (1) on transfer 2/17/2022
Screening questions:
Penicillin Allergy?

Yes
Nausea,
Vomiting,
or Diarrhea

What was your reaction?

Greater
than 10
years ago
Do not
know
No
No
No

When was your reaction?
Did your reaction happen after the 1st dose?

Did your reaction happen after several doses?
Did your reaction require ED or Hospital Care to treat your reaction?
Did your reaction require treatment with epinephrine?
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate (AUGMENTIN)
No
without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
No

The allergy was not actually added until 2 days following admission. However, the nurse answered yes
on the screening tool on admission to having a penicillin allergy.
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C.11 Patient 11. Brain Metastases
Penicillin allergy added10/29/12
“Questionable/ had a couple hives in age 20-30”
Admitted with headache 2/2/2022
Nurse Screening questions √
Allergy removed by ID Physician in anticipation of IV ABX 2/4/2022
“Patient Denied”
Entry determined to be clinically insignificant
Screening questions:
Penicillin Allergy?
Yes
None of the
What was your reaction?
Above, Please
Specify
Greater than 10
When was your reaction?
years ago
Did your reaction happen after the 1st dose?
Do not know
Did your reaction happen after several doses?
Do not know
Did your reaction require ED or Hospital Care to treat your reaction?
Do not know
Did your reaction require treatment with epinephrine?
Do not know
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate
Do not know
(AUGMENTIN) without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
Do not know

C.12 Patient 12 Lung mass/ Cavitary PNA
Penicillin allergy added1/31/2022 (1st time coming to Norton Facility)
Patient admitted for SOA 2/1/2022
Nurse Screening questions √
IV Unasyn start
Penicillin allergy deleted by nurse after tolerating IV Unasyn2/5/2022
Entry determined to be clinically insignificant
Screening questions:
Penicillin Allergy?
Yes
No
What was your reaction?
—
—
Greater than
When was your reaction?
10 years
—
ago
Did your reaction happen after the 1st dose?
Do not know —
Did your reaction happen after several doses?
Do not know —
Did your reaction require ED or Hospital Care to treat your reaction?
—
—
Did your reaction require treatment with epinephrine?
Do not know —
Have you taken Amoxicillin (AMOXIL) or amoxicillin-clavulanate
Do not know —
(AUGMENTIN) without issue since?
Have you taken cephalexin (KEFLEX) without issue since?
Do not know —
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C.13 Patient 13. Unknown
Penicillin allergy added
Allergy removed with comment added
“Tolerating ampicillin/sulbactam without issue Feb 2022”
Entry determined to be clinically insignificant
Screening questions:
Unknown
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